Publication: Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors
Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors
Date
Date
Date
Citations
Julius, U., Tselmin, S., Schatz, U., Fischer, S., & Bornstein, S. R. (2019). Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors. Clinical Research in Cardiology Supplements, 14(S1), 45–50. https://doi.org/10.1007/s11789-019-00099-z
Abstract
Abstract
Abstract
Lipoprotein(a) (Lp(a)) is an internationally accepted independent atherogenic risk factor. Details about its synthesis, many aspects of composition and clearance from the bloodstream are still unknown. LDL receptor (LDLR) (and probably other receptors) play a role in the elimination of Lp(a) particles. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors increase the number of available LDLRs and in this way very effectively reduce the LDL cholesterol (LDL-C) concentrations. As shown in controlled studies using PCSK9 inhib
Metrics
Additional indexing
Creators (Authors)
- Julius, U
- Tselmin, S
- Schatz, U
- Fischer, S
- Bornstein, S R
Journal/Series Title
Journal/Series Title
Journal/Series Title
Volume
Volume
Volume
Number
Number
Number
Page Range
Page Range
Page Range
Page end
Page end
Page end
Item Type
Item Type
Item Type
In collections
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Language
Language
Language
Publication date
Publication date
Publication date
Date available
Date available
Date available
ISSN or e-ISSN
ISSN or e-ISSN
ISSN or e-ISSN
OA Status
OA Status
OA Status
Free Access at
Free Access at
Free Access at
Publisher DOI
Metrics
Citations
Julius, U., Tselmin, S., Schatz, U., Fischer, S., & Bornstein, S. R. (2019). Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors. Clinical Research in Cardiology Supplements, 14(S1), 45–50. https://doi.org/10.1007/s11789-019-00099-z
